Effects of Lisdexamfetamine, a Prodrug of D-Amphetamine, on Locomotion, Spatial Cognitive Processing and Neurochemical Profiles in Rats: A Comparison With Immediate-Release Amphetamine

Jian-Min Chen, Zhiyuan Wang, Wu Shi-xuan, Rui Song, Ning Wu, Jin LiFrontiers in Psychiatry 2022 · DOI

Abstract

This study compares the cognitive and neurochemical effects of Lisdexamfetamine (LDX), a prodrug, against immediate-release D-amphetamine (D-AMP) in rats. While D-AMP is a common cognitive enhancer, its rapid absorption often leads to a narrow therapeutic window and high abuse potential. Using behavioral tasks and in vivo microdialysis, researchers found that LDX (4.5 mg/kg) significantly improved spatial working and recognition memory, whereas D-AMP failed to do so at any tested dose. These cognitive benefits are attributed to LDX's ability to induce a steadier, more sustained increase in dopamine levels within the medial prefrontal cortex (mPFC).

Introduction: The Challenge of Cognitive Enhancement

Psychostimulants like D-amphetamine are widely used to treat ADHD and as "cognitive enhancers." However, they are a double-edged sword. Rapid absorption creates sharp spikes in brain dopamine levels, leading to a narrow "effective window": too little dopamine is ineffective, while too much can impair cognition, cause excessive locomotor activity, or lead to addiction.

Lisdexamfetamine (LDX) was developed as a prodrug to address these issues. Inactive until metabolized by enzymes in red blood cells, LDX provides a "slow and steady" release of D-amphetamine. This study investigates whether this pharmacokinetic profile translates into superior cognitive enhancement compared to traditional immediate-release formulations.

Methods: Head-to-Head Comparison

Researchers administered equimolar doses of D-AMP (i.p.) and LDX (p.o.) to male Sprague-Dawley rats. The study evaluated:

  1. Locomotor Activity: To assess the drugs' stimulatory effects.
  2. Cognitive Tasks (Y-maze): Testing spatial working memory (spontaneous alternation) and spatial recognition memory (two-trial delayed alternation).
  3. Microdialysis: Measuring real-time changes in dopamine (DA) and its metabolites in the medial prefrontal cortex (mPFC).

Key Results

Locomotor Activity and Stimulation

The stimulatory effects of the two drugs differed significantly in timing and magnitude. D-AMP (0.5–1.5 mg/kg) caused an immediate, sharp increase in movement. In contrast, LDX (4.5 mg/kg) produced a delayed and more moderate increase in locomotion, reflecting its gradual metabolism.

Locomotor activity comparison between D-AMP (A, B) and LDX (C, D) across various doses. Significant increases are noted for D-AMP at 0.5-1.5 mg/kg and for LDX at 4.5 mg/kg.

Cognitive Performance: Memory Improvement

A critical finding was the dissociation between stimulation and cognition. While both drugs increased locomotion, only LDX improved memory. LDX at 4.5 mg/kg significantly enhanced both spatial working and recognition memory. Conversely, D-AMP failed to improve memory at any dose (0.2 to 13.5 mg/kg) and even impaired recognition memory at higher doses.

Neurochemical Profiles: The Role of Dopamine

Microdialysis revealed that D-AMP induced a massive, rapid dopamine spike (222% of baseline) that quickly subsided. LDX induced a more modest but sustained increase (177% of baseline), maintaining elevated levels for a longer duration. This steady-state release in the mPFC appears to be the mechanism underlying LDX's cognitive advantages.

Discussion: The "Goldilocks" Zone

The results support the "inverted U-shaped" theory of dopamine function, where cognition is optimized when dopamine levels are "just right." LDX’s prodrug nature keeps the brain in this optimal zone longer than D-AMP. Furthermore, the study highlights that "feeling stimulated" (increased locomotion) does not equate to improved cognitive performance.

Limitations and Future Directions

  • Acute vs. Chronic Dosing: This study utilized single doses; future work should examine the effects of chronic administration typical in clinical settings.
  • Route of Administration: The different routes (i.p. vs. p.o.) mimic typical usage but introduce absorption variables.
  • Neurotransmitter Systems: While the focus was on dopamine, the role of norepinephrine in the mPFC also warrants investigation to fully understand the "cognitive tuning" effects of these stimulants.

Summary updated

Abstract

D-amphetamine has been used to enhance cognitive performance over the last few decades. Due to the rapid absorption after administration, d-amphetamine shows narrow effective window and severe abuse potential. Lisdexamfetamine, a prodrug of d-amphetamine, reduces the magnitude of plasma d-amphetamine concentration and prolongs the action duration when compared with immediate-release d-amphetamine at equimolar doses. However, the differences of these two drugs, which produce distinct pharmacokinetic characteristics, in cognition improvement still unclear. In present study, we compared the effects of d-amphetamine (i.p) and lisdexamfetamine (p.o) at equimolar doses (0.2, 0.5, 1.5, 4.5, and 13.5 mg/kg of d-amphetamine base) on locomotion, spatial working memory and recognition memory in rats. Given the crucial involvement of dopamine neurotransmitter system within the medial prefrontal cortex (mPFC) in cognitive processing, microdialysis was conducted to profile the difference in neurochemical characteristics between the two drugs. In our results, d-amphetamine ranges from 0.5 to 1.5 mg/kg significantly increased locomotor activity. However, d-amphetamine ranges from 0.2 to 13.5 mg/kg failed to improve spatial working memory and recognition memory in Y-maze-based spontaneous alternation and two-trial delayed alternation tasks of rats, respectively. In contrast, lisdexamfetamine with 4.5 mg/kg significantly increased the locomotion and improved both spatial working and recognition memory. Further, microdialysis showed that lisdexamfetamine induced lower magnitude and longer duration of extracellular dopamine increase than that of d-amphetamine. These results suggest that lisdexamfetamine was more effective than d-amphetamine in improving spatial cognitive performance, which was attributed to the steady and lasting dopamine release pattern within the mPFC.
BibTeX
@inproceedings{chen2022effects,
  author = {Jian-Min Chen and Zhiyuan Wang and Wu Shi-xuan and Rui Song and Ning Wu and Jin Li},
  title = {{Effects of Lisdexamfetamine, a Prodrug of D-Amphetamine, on Locomotion, Spatial Cognitive Processing and Neurochemical Profiles in Rats: A Comparison With Immediate-Release Amphetamine}},
  booktitle = {Frontiers in Psychiatry},
  year = {2022},
  doi = {10.3389/fpsyt.2022.885574},
}
Figure